Oncotelic's PDAOAI Platform Targets AI Bias in Pharma with Evidence-Interrogation Approach
Oncotelic Therapeutics' PDAOAI platform indexes over 125,000 PubMed abstracts on TGF-β signaling to generate testable hypotheses, addressing transparency and bias challenges in AI-driven drug discovery.
The pharmaceutical industry's embrace of artificial intelligence is facing a critical test: how to ensure that AI-driven insights are transparent, reproducible, and free from the biases inherent in training data. Oncotelic Therapeutics Inc. (OTCQB: OTLC) has introduced a platform designed to tackle this challenge head-on, using an evidence-interrogation approach that prioritizes traceability over black-box predictions.
Oncotelic's PDAOAI platform indexes more than 125,000 PubMed abstracts on TGF-β signaling, a key pathway in cancer and fibrotic diseases. Instead of relying on predictive models trained on historical datasets, PDAOAI enables researchers to pose questions and retrieve direct evidence from the scientific literature, linking each hypothesis to its source. This hypothesis-first method aims to reduce training-set bias and build transparent, reproducible chains from question to evidence to hypothesis.
The platform's approach aligns with broader industry shifts. Recent coverage has placed Oncotelic alongside companies such as Rockwell Automation, Emerson Electric, Thermo Fisher Scientific, and Danaher as contributors to the pharmaceutical sector's move toward AI-integrated operations. Regulatory agencies are raising expectations around data integrity and traceability, while the industry shifts from retrospective audits toward continuous, AI-enabled monitoring systems. Manual processes and isolated datasets are no longer sufficient, according to Oncotelic, as scientific literature expands rapidly.
The implications for drug discovery are significant. By providing a retrieval-and-interrogation system rather than a traditional predictive model, PDAOAI allows researchers to identify patterns and generate testable hypotheses with direct links to the underlying literature. This could help address a core challenge in biotech research: the tendency for AI models to perpetuate biases present in their training data, leading to flawed or non-reproducible findings.
Oncotelic's focus on TGF-β signaling is particularly relevant, as this pathway is implicated in numerous diseases and has been a target for drug development. The platform's ability to surface evidence directly from PubMed abstracts could accelerate hypothesis generation and validation, potentially shortening the time from discovery to clinical testing.
The company's newsroom at ibn.fm/OTLC provides updates on its developments. As the pharmaceutical industry continues to integrate AI, platforms that prioritize transparency and evidence-based reasoning may become increasingly important for meeting regulatory expectations and improving the reproducibility of research.